TriangleNCT02841033 · OUTCOME
Time to Next Treatment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 3 years
What was measured
Number of months from study drug initiation to starting another treatment
Groups in this outcome
Daratumumab
Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month for up to 24 total cycles. Daratumumab: Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression, inability to tolerate, or 24 cycles completed.
| Group | Source count |
|---|---|
| Daratumumab | 22 |
Reported measurements
Source class 1
<12 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Daratumumab | 3 | Not reported | Not reported | Not reported | Not reported |
>12 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Daratumumab | 1 | Not reported | Not reported | Not reported | Not reported |
No further treatment
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Daratumumab | 18 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 3
- title
- <12 months
- measurements
- group Id
- OG000
- value
- 1
- title
- >12 months
- measurements
- group Id
- OG000
- value
- 18
- title
- No further treatment
- denoms
- counts
- group Id
- OG000
- value
- 22
- units
- Participants
- description
- Number of months from study drug initiation to starting another treatment
- groups
- description
- Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month for up to 24 total cycles. Daratumumab: Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression, inability to tolerate, or 24 cycles completed.
- id
- OG000
- title
- Daratumumab
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- Up to 3 years
- title
- Time to Next Treatment
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice